ATE329623T1 - Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium - Google Patents

Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium

Info

Publication number
ATE329623T1
ATE329623T1 AT02789260T AT02789260T ATE329623T1 AT E329623 T1 ATE329623 T1 AT E329623T1 AT 02789260 T AT02789260 T AT 02789260T AT 02789260 T AT02789260 T AT 02789260T AT E329623 T1 ATE329623 T1 AT E329623T1
Authority
AT
Austria
Prior art keywords
early stage
stage cancer
radiopharmaceutical agent
treating early
treating
Prior art date
Application number
AT02789260T
Other languages
English (en)
Inventor
Garry E Kiefer
Original Assignee
Dow Global Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Global Technologies Inc filed Critical Dow Global Technologies Inc
Application granted granted Critical
Publication of ATE329623T1 publication Critical patent/ATE329623T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02789260T 2001-10-22 2002-10-22 Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium ATE329623T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35559801P 2001-10-22 2001-10-22

Publications (1)

Publication Number Publication Date
ATE329623T1 true ATE329623T1 (de) 2006-07-15

Family

ID=23398047

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02789260T ATE329623T1 (de) 2001-10-22 2002-10-22 Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium

Country Status (6)

Country Link
US (1) US20030133872A1 (de)
EP (1) EP1438076B1 (de)
JP (1) JP2005507001A (de)
AT (1) ATE329623T1 (de)
DE (1) DE60212424T2 (de)
WO (1) WO2003035114A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005049096A2 (en) * 2003-11-14 2005-06-02 Dow Global Technologies Inc. Protein and polymer conjugates as chelants with enhanced blood retention
WO2006020779A2 (en) * 2004-08-10 2006-02-23 Dow Global Technologies Inc. Targeting chelants and chelates
KR102651945B1 (ko) * 2015-07-07 2024-03-26 파이브 일레븐 파마 인크. Hbed-비스포스포네이트, 이의 방사성금속 접합체 및 이의 진단치료제로서의 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994996A (en) * 1972-02-11 1976-11-30 Fmc Corporation Polymeric phosphazenes and process for preparation
DE3249091C2 (de) * 1981-10-05 1993-02-25 Sanwa Shutter Corp Hochziehbare Jalousie
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
US5362476A (en) * 1984-10-18 1994-11-08 Board Of Regents, The University Of Texas System Alkyl phosphonate polyazamacrocyclic cheates for MRI
US4779930A (en) * 1987-09-17 1988-10-25 Rosen Steven B Infant head support for use with infant retaining devices
US5739294A (en) * 1991-12-10 1998-04-14 The Dow Chemical Company Bicyclopol yazamacrocyclophosphonic acid complexes for use as contrast agents
US5428139A (en) * 1991-12-10 1995-06-27 The Dow Chemical Company Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals
US5714604A (en) * 1993-05-06 1998-02-03 The Dow Chemical Company Process for the preparation of azamacrocyclic or acyclic aminophosphonate ester derivatives
KR20000010533A (ko) * 1996-04-19 2000-02-15 텍사스 테크 유니버시티 시각적 조직 특이성 조영제로서의 형광 킬레이트
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
AU2002323528C1 (en) * 2001-09-04 2009-11-12 Texas Tech University Multi-use multimodal imaging chelates

Also Published As

Publication number Publication date
US20030133872A1 (en) 2003-07-17
DE60212424T2 (de) 2006-10-12
WO2003035114A1 (en) 2003-05-01
DE60212424D1 (de) 2006-07-27
EP1438076B1 (de) 2006-06-14
EP1438076A1 (de) 2004-07-21
JP2005507001A (ja) 2005-03-10

Similar Documents

Publication Publication Date Title
YU61701A (sh) Postupak i kit za efikasno radioobeležavanje proteina sa terapeutskim radioizotopom
GEP20032897B (en) Epothilone Derivatives
DK0836485T3 (da) Kaskade-polymer-komplekser, fremgangsmåde til deres fremstilling og farmaceutiske midler indeholdende disse
DK1644049T3 (da) Fremgangsmåde og anordning til radioterapi
NO20054988D0 (no) Preparater og metoder for behandling av cancer
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
ATE296839T1 (de) Antikörper zur krebsbehandlung und -diagnose
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DE69533066D1 (de) Verbindungen und verfahren zur behandlung von krebs
TW200518752A (en) Combinations of drugs for the treatment of neoplasms
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
DE69942742D1 (de) Immuntherapeutische zusammensetzung und verfahren zur behandlung von prostatakrebs
DE602004025726D1 (de) Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
DE69716104D1 (de) Chelate und metalchelate zur behandlung von durch freie radikale verursachte zustände
EA200401525A1 (ru) Способы лечения гепатита (варианты )
WO2004033666A3 (en) Method and compounds for inhibiting hec1 activity for the treatment of proliferative diseases
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
DK1237562T3 (da) Fremgangsmåde til fremstilling af mikania-ekstrakter, som indeholder mikanolid og dihydromikanolid, og anvendelse i behandlingen af prolifererende sygdomme
DE60212424D1 (de) Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
ATE283920T1 (de) Verfahren zur immunisierung und behandlung von h. pylori infektion
DE60144493D1 (de) Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
DE60331654D1 (de) Nicht-radioaktives Strontiummittel zur Behandlung von Krebs
DE60109594D1 (de) R-eliprodil zur behandlung von glaucoma

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties